Literature DB >> 15911357

The clinical spectrum and natural history of gelastic epilepsy-hypothalamic hamartoma syndrome.

Salvatore Striano1, Pasquale Striano, Chiara Sarappa, Patrizia Boccella.   

Abstract

PURPOSE: To delineate the clinical spectrum and patterns of evolution of epilepsy with gelastic seizures related to hypothalamic hamartoma (HH). PATIENTS AND METHODS: We evaluated patients with HH, observed between 1986 and 2002 for whom at least one ictal video-EEG or EEG recording of gelastic seizures was available.
RESULTS: Six subjects (four male, two female) with sessile HH between 0.8 and 1.7 cm in diameter were identified. The onset of gelastic seizures was between 2 months and 20 years. It evolved to secondary generalized epilepsy in one case, and to drug-resistant partial epilepsy in the other five from 2 to 13 years after onset. No patient showed precocious puberty. Severe cognitive impairment developed in the patient with secondary generalized epilepsy, and a mild cognitive defect in two others. Patients with an HH below 1cm did not show neuropsychological or behavioural disturbances. Drug resistance occurred in all cases. Surgical removal of HH markedly improved the clinical evolution in two patients.
CONCLUSIONS: Gelastic epilepsy-HH syndrome can differ in severity and evolution. A catastrophic evolution and drug resistance can be reversed by surgical or by gamma-knife ablation of HH.

Entities:  

Mesh:

Year:  2005        PMID: 15911357     DOI: 10.1016/j.seizure.2005.01.004

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  11 in total

1.  Robotic-arm stereotactic radiosurgery as a definitive treatment for gelastic epilepsy associated with hypothalamic hamartoma.

Authors:  Sridhar Papaiah Susheela; Swaroop Revannasiddaiah; Govindarajan J Mallarajapatna; Ajaikumar Basavalingaiah
Journal:  BMJ Case Rep       Date:  2013-09-11

2.  Inappropriate Laughter and Behaviours: How, What, and Why? Case of an Adult with Undiagnosed Gelastic Seizure with Hypothalamic Hamartoma.

Authors:  Nina L Beckwith; Jaclyn C Khil; Jason Teng; Kore K Liow; Alice Smith; Jesus Luna
Journal:  Hawaii J Med Public Health       Date:  2018-12

Review 3.  Mechanisms of intrinsic epileptogenesis in human gelastic seizures with hypothalamic hamartoma.

Authors:  Jie Wu; Ming Gao; Jian-Xin Shen; Shen-Feng Qiu; John F Kerrigan
Journal:  CNS Neurosci Ther       Date:  2014-12-12       Impact factor: 5.243

4.  Transcallosal resection of hypothalamic hamartoma for gelastic epilepsy.

Authors:  M Andrew; J R Parr; R Stacey; J V Rosenfeld; Y Hart; P Pretorius; S Nijhawan; Z Zaiwalla; M A McShane
Journal:  Childs Nerv Syst       Date:  2007-09-09       Impact factor: 1.475

5.  A case of pure gelastic seizures due to hypothalamic hamartoma with a benign course.

Authors:  T D Gosavi; M C Walker
Journal:  Epilepsy Behav Case Rep       Date:  2017-06-16

6.  An 11-month-old girl with central precocious puberty caused by hypothalamic hamartoma.

Authors:  Da Young Yoon; Jae Hyun Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-12-31

7.  Hypothalamic hamartomas in adulthood: Clinical spectrum and treatment outcome-A unicenter experience.

Authors:  Estefanía Conde Blanco; Carla Anciones Martín; Isabel Manzanares; Francisco Gil López; Pedro Roldán; Antonio Donaire; Jordi Rumiá; Mar Carreño
Journal:  Brain Behav       Date:  2019-10-02       Impact factor: 2.708

Review 8.  Neuropsychological features of lesion-related epilepsy in adults: an overview.

Authors:  Chris E Morrison; Luba Nakhutina
Journal:  Neuropsychol Rev       Date:  2007-10-19       Impact factor: 6.940

9.  Gelastic seizures associated with hypothalamic hamartomas. An update in the clinical presentation, diagnosis and treatment.

Authors:  José F Téllez-Zenteno; Cesar Serrano-Almeida; Farzad Moien-Afshari
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Gap Junctions and Epileptogenesis: No Laughing Matter.

Authors:  Elisabetta Gazzerro; Pasquale Striano
Journal:  EBioMedicine       Date:  2016-05-24       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.